Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | ESMO 2025: breakthrough ADC trials in TNBC and HER2+ breast cancer

Erika Hamilton • 17 Oct 2025
ESMO 2025
Breast Cancer Sacituzumab govitecan Trastuzumab deruxtecan
DESTINY-Breast05 DESTINY-Breast11

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, highlights the latest developments in antibody-drug conjugates (ADCs) presented at ESMO 2025, focusing on trials such as DESTINY-Breast11 (NCT05113251) and DESTINY-Breast05 (NCT04622319) that are advancing trastuzumab-drug conjugates into the curative setting for HER2-positive breast cancer. Dr Hamilton also covers the movement of ADCs into earlier lines of treatment for triple-negative breast cancer, including first-line use of sacituzumab govitecan, with recent positive trial results. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Erika Hamilton

Breast cancer updates at ASCO 2026: KEYNOTE-522, SERENA-6, and more
1:50
Breast cancer updates at ASCO 2026: KEYNOTE-522, SERENA-6, and more
Erika Hamilton • 5 Jun 2026
Optimizing sequencing & maintenance strategies in HER2+ metastatic breast cancer
2:21
Optimizing sequencing & maintenance strategies in HER2+ metastatic breast cancer
Erika Hamilton • 5 Jun 2026
HER2CLIMB-05: subgroup analyses of tucatinib, trastuzumab & pertuzumab in HER2+ mBC
4:01
HER2CLIMB-05: subgroup analyses of tucatinib, trastuzumab & pertuzumab in HER2+ mBC
Erika Hamilton • 5 Jun 2026
Sequencing HER2+ therapies in breast cancer: insights on ADCs, TKIs, chemo, & maintenance strategies
1:25
Sequencing HER2+ therapies in breast cancer: insights on ADCs, TKIs, chemo, & maintenance strategies
Erika Hamilton • 10 Dec 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals